Dermatologicals Top Workers Comp Drug Costs: Study

Why It Matters

The surge in dermatology drug costs pressures workers‑comp insurers and employers, prompting a reevaluation of pharmacy benefit designs. Understanding channel concentration and state‑level variation is essential for cost‑containment strategies.

Key Takeaways

• Dermatology drugs made up 23% of workers comp prescription spend median state
• Physician dispensing and delivery pharmacies handled over 70% of dermatology payments
• Prescription payments per claim rose 24% to $63, up from $51
• Claims ranged $14 in Minnesota to $353 in Louisiana
• Migraine drugs are rising cost drivers while opioid payments keep declining

Pulse Analysis

The workers‑compensation market is witnessing a notable shift as dermatological agents become the primary cost driver for prescription drugs. While nonsteroidal anti‑inflammatory drugs (NSAIDs) still account for a sizable share, dermatology products now capture roughly a quarter of total spend in a typical state and over a third in the most affected jurisdictions. This concentration is amplified by the dominance of physician‑dispensing and delivery‑pharmacy models, which together funnel more than 70% of dermatology payments, creating a streamlined but costly distribution pathway.

State‑by‑state analysis reveals pronounced disparities that insurers must navigate. Minnesota’s per‑claim drug cost sits at a modest $14, whereas Louisiana’s climbs to $353, reflecting divergent pricing, formulary management, and local prescribing habits. Overall, the median claim cost rose 24% to $63 between 2022 and 2025, ending years of modest declines. These variations compel employers and carriers to tailor benefit designs, negotiate channel‑specific rebates, and consider geographic risk adjustments to mitigate exposure.

Beyond dermatology, emerging therapeutic categories are reshaping the cost landscape. Migraine medications are gaining traction as a growing expense, while opioid payments continue to fall, albeit at a slower pace than in previous years. This evolving mix suggests that future cost‑containment efforts will need to balance traditional high‑volume drugs with newer, high‑price specialty treatments. Stakeholders are likely to increase focus on utilization management, alternative distribution channels, and value‑based contracts to curb rising outlays while maintaining access for injured workers.